|
|
P.O.Box 3048
Caesarea Industrial Park, 38900 Israel
phone:972-4-6373979
fax:972-4-6373878
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
2006 |
| Employees |
12 |
|
|
| www.life-bond.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Biocompatible Hemostatic Bandages and Adhesive Sealants |
|
| Management |
| Dr Doron Kopelman, Medical Director; Ishay Attar, CEO, Founder; Orahn Preiss-Bloom, VP Operations, Founder; Dr. Rafi Hofstein, Ph.D, Chairman |
| |
|
|
| |
|
| Keywords |
| adhesive, sealant, wound care, biocompatible, hemostat, bandage |
|
|
|
| Description |
|
LifeBond develops next-generation biosurgical products to ease wound closure and stimulate hemostasis. The company's product line is composed of surgical sealants and active hemostats which incorporate a proprietary adhesive formulation mimicking the biochemical cross-linking cascade of late stage blood coagulation. |
|
| Products / Services |
Lifebond's adhesive sealant forms a network similar to the fibrin network of blood clots but has demonstrated adhesive strength even greater than that of blood-derived fibrin sealants. It can strongly adhere to tissue even after several weeks in a physiological environment. The company's technology is distributed via the LifeSeal and LifePatch product lines. The LifePatch, comprised of a lyophilized matrix containing LifeBond sealant components, is applied to a bleeding or leaking injury site where the sealant components are rapidly reconstituted into a firm adhesive gel for reliable hemostasis. LifeSeal Surgery is comprised of LifeBond sealant provided in a specialized two-component applicator syringe; this mixed sealant is applied to anastomotic staple-line junctures to fortify the attachment and to prevent leakage until full physiological function is restored. The applicator thoroughly mixes the two components as they are applied and evenly dispenses the sealant onto the wound site or staple-line juncture. The precise application method can be altered to optimize sealant use for specific applications.
|
|
| Technology / Differentiation |
| LifeBond's technology functions via the rapid and biocompatible in situ cross-linking of structural proteins. The sealant undergoes cross-linking independent of blood factors, ensuring reliable hemostasis even in the presence of anti-clotting factors. Proteins in the physiological environment undergo a gelation process, forming an adhesive hydrogel matrix while cross-linking. The properties of the cross-linking reaction and the hydrogel matrix can be controlled to fit a variety of applications. |
|
| Market / Customers |
The U.S. surgical sealant market represents 3.5 million procedures, while between 6 to 7 million absorbable surgical hemostats are used each year. Leakage rates are above 10% in the most common leakage-prone procedures (i.e., vascular anastomosis and dura reconstruction), resulting in life-threatening surgical complications. Successful techniques of reducing or avoiding blood transfusion can drastically improve patient outcomes. Lifebond is responding to the largely unmet need for easy-to-use, stable, integrated and absorbable hemostats with sufficient adhesiveness to stay in place on a wound site without getting displaced by flowing blood.
|
|
| Status |
| LifeBond expects to receive FDA regulatory approval for its hemostatic bandages sometime in 2009. The company raised $1.5 million in August 2007 from GlenRock Israel and The Zitelman Group of the U.S. Although its products meet needs in various areas, LifeBond develops specific medical adhesive, surgical sealan, and absorbable hemostat products with consideration for regulatory guidelines and market need. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members